Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
暂无分享,去创建一个
Katy Rezvani | David A Largaespada | Jianliang Dai | K. Do | D. Largaespada | D. Marin | H. Kantarjian | E. Shpall | B. Moriarity | M. Keating | Y. Nieto | U. Popat | M. Qazilbash | P. Hackett | A. Alousi | W. Wierda | S. Olivares | Harjeet Singh | Dean Anthony Lee | R. Champlin | L. Cooper | R. Bassett | K. Rezvani | M. Forget | Hagop Kantarjian | Amin Alousi | Partow Kebriaei | Uday Popat | Chitra Hosing | Yago Nieto | Laurence J N Cooper | Gabriela Rondon | Stefan Ciurea | Elizabeth J Shpall | David Marin | Roland Bassett | Perry B Hackett | Marie-Andrée Forget | S. Maiti | Michael Keating | William Wierda | Branden Moriarity | Harjeet Singh | Matthew J. Figliola | Margaret J. Dawson | Simon Olivares | Sourindra Maiti | Vladimir Senyukov | Bipulendu Jena | Judy S Moyes | G. Rondón | C. Hosing | P. Kebriaei | S. Ciurea | Kim Anh Do | Jianliang Dai | M Helen Huls | Pappanaicken R Kumaresan | P. Kumaresan | Richard E Champlin | B. Jena | Muzaffar Qazilbash | Dean A Lee | Matthew J Figliola | Margaret J Dawson | Shihuang Su | Aaron Orozco | Tingting Liu | Jessica McCarty | Rineka N Jackson | M. H. Huls | A. Orozco | J. McCarty | J. Moyes | R. Jackson | Tingting Liu | S. Su | Vladimir Senyukov | Bipulendu Jena | G. Rondon
[1] S. Rosenberg,et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Fry,et al. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. , 2016, Blood.
[3] T. Fry,et al. Challenges and opportunities of allogeneic donor-derived CAR T cells , 2015, Current opinion in hematology.
[4] Daniel W. Lee,et al. Paving the road ahead for CD19 CAR T-cell therapy , 2015, Current opinion in hematology.
[5] A. Bagg,et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. , 2015, The New England journal of medicine.
[6] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[7] Sonali M. Smith,et al. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] S. Mineishi,et al. Seatbelts in CAR therapy: How Safe Are CARS? , 2015, Pharmaceuticals.
[9] A. Zelenetz,et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. , 2015, Blood.
[10] Xiuli Wang,et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[13] Allen R. Chen,et al. Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic Malignancies , 2015 .
[14] Harjeet Singh,et al. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor , 2015, Cancer Gene Therapy.
[15] M. Konopleva,et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[17] R. Chemaly,et al. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation , 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[18] J. Harty,et al. Impact of Inflammatory Cytokines on Effector and Memory CD8+ T Cells , 2014, Front. Immunol..
[19] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[20] M. Valsecchi,et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? , 2014, British journal of haematology.
[21] Harjeet Singh,et al. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19 , 2014, Immunological reviews.
[22] C. Cruz,et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.
[23] E. Shpall,et al. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] S. Olivares,et al. Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells , 2013, PloS one.
[25] Bernat Gel,et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and genetic pathways driving tumorigenesis , 2013, Nature Genetics.
[26] E. Shpall,et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia , 2013, Bone Marrow Transplantation.
[27] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[28] David A Largaespada,et al. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. , 2013, Translational research : the journal of laboratory and clinical medicine.
[29] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[30] L. Monasta,et al. Cytokine Levels in the Serum of Healthy Subjects , 2013, Mediators of inflammation.
[31] J. Rowe,et al. The myth of the second remission of acute leukemia in the adult. , 2013, Blood.
[32] A. Multani,et al. Sleeping Beauty System to Redirect T-cell Specificity for Human Applications , 2013, Journal of immunotherapy.
[33] E. Shpall,et al. Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood , 2013, Journal of visualized experiments : JoVE.
[34] J. Wingard,et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] P. Hwu,et al. A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy , 2012, Clinical Cancer Research.
[36] M. Labopin,et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT , 2012, Leukemia.
[37] E. Shpall,et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. , 2012, Human gene therapy.
[38] Jinjuan Wang,et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.
[39] W. Wilson,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[40] P. Kebriaei,et al. The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia , 2012, Current Hematologic Malignancy Reports.
[41] L. Hurton,et al. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.
[42] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[43] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[44] Sungha Park,et al. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays , 2011, Journal of Translational Medicine.
[45] Hao Liu,et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.
[46] W. Wilson,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.
[47] M. Kalos,et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[48] Z. Izsvák,et al. Translating Sleeping Beauty transposition into cellular therapies: Victories and challenges , 2010, BioEssays : news and reviews in molecular, cellular and developmental biology.
[49] G. Dotti,et al. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. , 2010, Blood.
[50] H. Putter,et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation , 2010, Leukemia.
[51] M. Sadelain,et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[52] S. Rosenberg,et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[53] P. Rao,et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. , 2010, Human gene therapy.
[54] Boris Jerchow,et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates , 2009, Nature Genetics.
[55] Jinjuan Wang,et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.
[56] B. Dörken,et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy , 2008, Bone Marrow Transplantation.
[57] Allen R. Chen,et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[58] E. Shpall,et al. System Sleeping Beauty the Redirecting Specificity of T-cell Populations for Cd19 Using Cited Articles Citing Articles E-mail Alerts Redirecting Specificity of T-cell Populations for Cd19 Using the Sleeping Beauty System , 2022 .
[59] H. Dombret,et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.
[60] Rajesh Chopra,et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.
[61] David D. Smith,et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.
[62] J. Tolar,et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. , 2005, Blood.
[63] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[64] D. Largaespada,et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[65] P. Martiat,et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study , 2003, Bone Marrow Transplantation.
[66] J. Klein,et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia , 1998, Bone Marrow Transplantation.
[67] R. Plasterk,et al. Molecular Reconstruction of Sleeping Beauty , a Tc1-like Transposon from Fish, and Its Transposition in Human Cells , 1997, Cell.
[68] Appelbaum Fr. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). , 1997 .
[69] Robert H. Collins,et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] F. Appelbaum. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). , 1997, Leukemia.
[71] A. Deisseroth,et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. , 1996, Blood.
[72] S W Lagakos,et al. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. , 1982, Biometrics.